rheumatology
Osteoarthritis

Low-dose meloxicam approved for OA

A low-dose formulation of meloxicam for the treatment of osteoarthritis pain has been approved by the FDA. The medication marketed in the US as Vivlodex by Iroko pharmaceuticals is made using a proprietary technology for producing submicron-size particles of meloxicam that are 10 times smaller than their traditional size. According to company information the reduction ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic